Here, we showed that Ezh2 inhibition by DZNEP could reduce Doc-induced gene expression of cancer stem cell markers (Nanog, CD44 and Sox2), supporting the notion that Ezh2 acts on these genes independent of PRC2 complex. The gene discussed is NANOG; the disease is cancer.